Cargando…

Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker

Previous diffusion tensor imaging (DTI) studies have shown white matter pathology in amyotrophic lateral sclerosis (ALS), predominantly in the motor pathways. Further these studies have shown that DTI can be used longitudinally to track pathology over time, making white matter pathology a candidate...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhinav, Kumar, Yeh, Fang-Cheng, El-Dokla, Ahmed, Ferrando, Lisa M., Chang, Yue-Fang, Lacomis, David, Friedlander, Robert M., Fernandez-Miranda, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010737/
https://www.ncbi.nlm.nih.gov/pubmed/24808852
http://dx.doi.org/10.3389/fnhum.2014.00270
_version_ 1782479896167055360
author Abhinav, Kumar
Yeh, Fang-Cheng
El-Dokla, Ahmed
Ferrando, Lisa M.
Chang, Yue-Fang
Lacomis, David
Friedlander, Robert M.
Fernandez-Miranda, Juan C.
author_facet Abhinav, Kumar
Yeh, Fang-Cheng
El-Dokla, Ahmed
Ferrando, Lisa M.
Chang, Yue-Fang
Lacomis, David
Friedlander, Robert M.
Fernandez-Miranda, Juan C.
author_sort Abhinav, Kumar
collection PubMed
description Previous diffusion tensor imaging (DTI) studies have shown white matter pathology in amyotrophic lateral sclerosis (ALS), predominantly in the motor pathways. Further these studies have shown that DTI can be used longitudinally to track pathology over time, making white matter pathology a candidate as an outcome measure in future trials. DTI has demonstrated application in group studies, however its derived indices, for example fractional anisotropy, are susceptible to partial volume effects, making its role questionable in examining individual progression. We hypothesize that changes in the white matter are present in ALS beyond the motor tracts, and that the affected pathways and associated pattern of disease progression can be tracked longitudinally using automated diffusion connectometry analysis. Connectometry analysis is based on diffusion spectrum imaging and overcomes the limitations of a conventional tractography approach and DTI. The identified affected white matter tracts can then be assessed in a targeted fashion using High definition fiber tractography (a novel white matter MR imaging technique). Changes in quantitative and qualitative markers over time could then be correlated with clinical progression. We illustrate these principles toward developing an imaging biomarker for demonstrating individual progression, by presenting results for five ALS patients, including with longitudinal data in two. Preliminary analysis demonstrated a number of changes bilaterally and asymmetrically in motoric and extramotoric white matter pathways. Further the limbic system was also affected possibly explaining the cognitive symptoms in ALS. In the two longitudinal subjects, the white matter changes were less extensive at baseline, although there was evidence of disease progression in a frontal pattern with a relatively spared postcentral gyrus, consistent with the known pathology in ALS.
format Online
Article
Text
id pubmed-4010737
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40107372014-05-07 Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker Abhinav, Kumar Yeh, Fang-Cheng El-Dokla, Ahmed Ferrando, Lisa M. Chang, Yue-Fang Lacomis, David Friedlander, Robert M. Fernandez-Miranda, Juan C. Front Hum Neurosci Neuroscience Previous diffusion tensor imaging (DTI) studies have shown white matter pathology in amyotrophic lateral sclerosis (ALS), predominantly in the motor pathways. Further these studies have shown that DTI can be used longitudinally to track pathology over time, making white matter pathology a candidate as an outcome measure in future trials. DTI has demonstrated application in group studies, however its derived indices, for example fractional anisotropy, are susceptible to partial volume effects, making its role questionable in examining individual progression. We hypothesize that changes in the white matter are present in ALS beyond the motor tracts, and that the affected pathways and associated pattern of disease progression can be tracked longitudinally using automated diffusion connectometry analysis. Connectometry analysis is based on diffusion spectrum imaging and overcomes the limitations of a conventional tractography approach and DTI. The identified affected white matter tracts can then be assessed in a targeted fashion using High definition fiber tractography (a novel white matter MR imaging technique). Changes in quantitative and qualitative markers over time could then be correlated with clinical progression. We illustrate these principles toward developing an imaging biomarker for demonstrating individual progression, by presenting results for five ALS patients, including with longitudinal data in two. Preliminary analysis demonstrated a number of changes bilaterally and asymmetrically in motoric and extramotoric white matter pathways. Further the limbic system was also affected possibly explaining the cognitive symptoms in ALS. In the two longitudinal subjects, the white matter changes were less extensive at baseline, although there was evidence of disease progression in a frontal pattern with a relatively spared postcentral gyrus, consistent with the known pathology in ALS. Frontiers Media S.A. 2014-04-29 /pmc/articles/PMC4010737/ /pubmed/24808852 http://dx.doi.org/10.3389/fnhum.2014.00270 Text en Copyright © 2014 Abhinav, Yeh, El-Dokla, Ferrando, Chang, Lacomis, Friedlander and Fernandez-Miranda. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Abhinav, Kumar
Yeh, Fang-Cheng
El-Dokla, Ahmed
Ferrando, Lisa M.
Chang, Yue-Fang
Lacomis, David
Friedlander, Robert M.
Fernandez-Miranda, Juan C.
Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title_full Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title_fullStr Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title_full_unstemmed Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title_short Use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
title_sort use of diffusion spectrum imaging in preliminary longitudinal evaluation of amyotrophic lateral sclerosis: development of an imaging biomarker
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010737/
https://www.ncbi.nlm.nih.gov/pubmed/24808852
http://dx.doi.org/10.3389/fnhum.2014.00270
work_keys_str_mv AT abhinavkumar useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT yehfangcheng useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT eldoklaahmed useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT ferrandolisam useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT changyuefang useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT lacomisdavid useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT friedlanderrobertm useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker
AT fernandezmirandajuanc useofdiffusionspectrumimaginginpreliminarylongitudinalevaluationofamyotrophiclateralsclerosisdevelopmentofanimagingbiomarker